Rheumatoid PurpuraPREEMSNCT05737056
Rheumatoid Purpura in Children: a Multicenter Observational Study of Pediatric Emergency Department Management and Follow-up by Primary Care Physicians
An observational study of Rheumatoid Purpura, run by Groupe Hospitalier de la Region de Mulhouse et Sud Alsace at 2 sites in France.
Trial summary
The main objective of this study is to describe the management of children with rheumatoid purpura from admission to the pediatric emergency room to follow-up by primary care physicians after hospital discharge. Read more about this study
- Who is it for?
- Ages 0 to 18 years
- Conditions the study is for
- Rheumatoid Purpura
- What is being tested?
- Management of rheumatoid purpura
- How many people
- 66 participants
- Where
- 2 sitesFrance
- Study dates
- 9 May 2023to 28 Jul 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Patients will be identified by the Medical Information Department of each site. The study will be conducted on patients who have been managed for rheumatoid purpura within the last two years at one of the three participating centers.
Who may be able to join
- Underaged patient diagnosed with rheumatoid purpura during a visit to the pediatric emergencies of Mulhouse, Colmar and Strasbourg
- No objection to the study from the two holders of parental authority
Who cannot join
- Patient followed in the context of a genetic or malformative pathology, an immune deficiency, or a cancer
Trial locations and contacts
2 sites in 1 country.
France2 sites
Hôpitaux Civils de Colmar
Colmar, 68000
Hôpital de Hautepierre
Strasbourg, 67200
About this study
The main objective of this study is to describe the management of children with rheumatoid purpura from admission to the pediatric emergency room to follow-up by primary care physicians after hospital discharge.
Read the detailed description
Secondary objectives The secondary objective is to assess general practitioners current knowledge and practice of the condition and potential barriers to monitoring and follow-up by general practitioners.
Conduct of research Children diagnosed with rheumatoid purpura within the past 2 years at the 3 participating sites will be included in the study if parental authority holders do not object.
Patients will be identified through the Medical Information Department of each hospital.
Parents will be contacted - first by mail, then by phone - to request permission to collect the child's medical data from medical records, and to retrieve information on the surveillance and follow-up of the disease by general practitioners up to two years after diagnosis.
- Conditions
- Rheumatoid Purpura
- Being tested
- Management of rheumatoid purpura
- Medical subject headings
- IgA Vasculitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Management of rheumatoid purpuraOther
Collection of data on the management in pediatric emergency departments (method of diagnosis, complementary examinations, proposed treatment, number of hospitalizations, follow-up after hospital discharge).
| Study group | Role | What they receive |
|---|---|---|
| Children diagnosed with rheumatoid purpura at the pediatric emergency department | Children diagnosed with rheumatoid purpura from admission to the pediatric emergency department up to two years of follow-up by general practitioners after hospital discharge. Receives: Other: Management of rheumatoid purpura |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compliance with the recommendations for the management of rheumatoid purpura
Measured: Up to two years after hospital discharge
Secondary outcomes (1)
Knowledge assessment questionnaire regarding rheumatoid purpura
Evaluation of the knowledge and current practices of general practitioners regarding rheumatoid purpura and identification of the possible obstacles to management and follow-up in primary care, using an online survey
Measured: At the beginning of the study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2023
- Study start9 May 2023
- Primary completion28 Jul 2023
- Study completion28 Jul 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rheumatoid PurpuraStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 66 participants (actual)
Sponsor and investigators
- Lead sponsor
- Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05737056
- Sponsor's protocol ID
- GHRMSA 1278
- Other IDs
- 2022-A02687-36
- Acronym
- PREEMS
- Status last verified
- Oct 2023
- First submitted
- 10 Feb 2023
- Last updated
- 20 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Rheumatoid Purpura in Children: a Multicenter Observational Study of Pediatric Emergency Department Management and Follow-up by Primary Care Physicians
- ClinicalTrials.gov ID
- NCT05737056
- Acronym / sponsor ID
- PREEMS / GHRMSA 1278
- Conditions
- Rheumatoid Purpura
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 66 participants (actual)
- Lead sponsor
- Groupe Hospitalier de la Region de Mulhouse et Sud AlsaceUniversity, hospital or other
- Study start
- 9 May 2023 (actual)
- Primary completion
- 28 Jul 2023 (actual)
- Study completion
- 28 Jul 2023 (actual)
- First posted
- 21 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of this study is to describe the management of children with rheumatoid purpura from admission to the pediatric emergency room to follow-up by primary care physicians after hospital discharge.
Detailed description
Secondary objectives The secondary objective is to assess general practitioners current knowledge and practice of the condition and potential barriers to monitoring and follow-up by general practitioners.
Conduct of research Children diagnosed with rheumatoid purpura within the past 2 years at the 3 participating sites will be included in the study if parental authority holders do not object.
Patients will be identified through the Medical Information Department of each hospital.
Parents will be contacted - first by mail, then by phone - to request permission to collect the child's medical data from medical records, and to retrieve information on the surveillance and follow-up of the disease by general practitioners up to two years after diagnosis.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Children diagnosed with rheumatoid purpura at the pediatric emergency department | – | Other: Management of rheumatoid purpuraChildren diagnosed with rheumatoid purpura from admission to the pediatric emergency department up to two years of follow-up by general practitioners after hospital discharge. |
Who may qualify
- Ages
- 0 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Patients will be identified by the Medical Information Department of each site. The study will be conducted on patients who have been managed for rheumatoid purpura within the last two years at one of the three participating centers.
Key inclusion criteria (2 listed)
- Underaged patient diagnosed with rheumatoid purpura during a visit to the pediatric emergencies of Mulhouse, Colmar and Strasbourg
- No objection to the study from the two holders of parental authority
Key exclusion criteria (1 listed)
- Patient followed in the context of a genetic or malformative pathology, an immune deficiency, or a cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Management of rheumatoid purpuraCollection of data on the management in pediatric emergency departments (method of diagnosis, complementary examinations, proposed treatment, number of hospitalizations, follow-up after hospital discharge). | Other | Children diagnosed with rheumatoid purpura at the pediatric emergency department |
Primary outcome
Compliance with the recommendations for the management of rheumatoid purpura
Time frame: Up to two years after hospital discharge
1 secondary outcome
Knowledge assessment questionnaire regarding rheumatoid purpura
Time frame: At the beginning of the study
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Nov 2025.
- Study resultsLink provided by the sponsor.
Related trials for Rheumatoid Purpura
Enrolling by invitationObservational study
Comparative Autoantibody and Immunologic Cell Marker Study
Autoimmune Diseases, Lupus Erythematosus, Systemic
Active, not recruitingPhase 1
Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions
Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP)
Not yet recruiting
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies
RecruitingEarly Phase 1
Safety Study of CC312 in Autoimmune Disease Patients
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
RecruitingPhase 2
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Systemic Lupus Erythematosus, Inflammatory Myopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Rheumatoid Purpura, run by Groupe Hospitalier de la Region de Mulhouse et Sud Alsace at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compliance with the recommendations for the management of rheumatoid purpura (time frame: Up to two years after hospital discharge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2025.